Structure Therapeutics (NASDAQ:GPCR) Posts Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Structure Therapeutics (NASDAQ:GPCR) announced its earnings results on Thursday. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14), Zacks reports.

Structure Therapeutics Trading Down 2.2%

GPCR stock traded down $1.41 during mid-day trading on Friday, reaching $63.34. 285,349 shares of the stock traded hands, compared to its average volume of 1,062,554. The company has a market cap of $4.47 billion, a P/E ratio of -52.03 and a beta of -2.06. Structure Therapeutics has a 52-week low of $13.22 and a 52-week high of $94.90. The stock’s fifty day moving average is $75.45 and its 200-day moving average is $46.22.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GPCR shares. Guggenheim raised their target price on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. JPMorgan Chase & Co. raised their price target on Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Thursday, January 22nd. Finally, Stifel Nicolaus lifted their price objective on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.50.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP boosted its holdings in Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after purchasing an additional 1,432,797 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Structure Therapeutics by 14.4% in the 4th quarter. Janus Henderson Group PLC now owns 5,090,148 shares of the company’s stock valued at $354,006,000 after purchasing an additional 641,322 shares in the last quarter. Morgan Stanley increased its holdings in shares of Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after buying an additional 1,510,093 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Structure Therapeutics by 477.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock valued at $116,228,000 after purchasing an additional 1,381,745 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in Structure Therapeutics by 7.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock worth $32,939,000 after buying an additional 106,389 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.